Tonix Pharmaceuticals Holding Earnings Call Transcripts
Fiscal Year 2026
-
Achieved first-in-class approval and strong early sales for a fibromyalgia drug, with accelerating Q2 trends and broadening payer coverage. Digital marketing and a growing sales force support expansion, while a large addressable market and pipeline for Lyme disease prevention offer significant long-term potential.
-
A new fibromyalgia therapy has launched with positive early adoption and broad prescriber engagement, supported by robust patient access and a dynamic commercial strategy. The pipeline includes a promising Lyme disease prevention antibody, and financial resources are strong.
-
Tonmya, a novel sublingual treatment for fibromyalgia, launched with strong commercial focus and early sales, targeting a large unmet need and potential long COVID expansion. The pipeline includes a Lyme prophylactic, depression, and transplant programs, with major milestones expected by 2027.
Fiscal Year 2025
-
Tonmya, a new sublingual treatment for fibromyalgia, is set for imminent US launch, supported by strong clinical data and a robust commercial strategy. The pipeline includes programs in CNS, immunology, infectious disease, and rare disease, with multiple studies starting in 2024.
-
Tonmya recently received FDA approval for fibromyalgia and is being launched with a focus on providers who treat the majority of diagnosed patients. The product differentiates itself through a unique mechanism, improved tolerability, and non-opioid status, aiming to address significant unmet needs and reduce opioid reliance.
-
FDA approved Tonmya, a first-in-class, non-opioid sublingual treatment for fibromyalgia, following robust phase III trials. The company is launching with a 90-person sales force, targeting both diagnosed and undiagnosed patients, and expects commercial availability next quarter.
-
Fast Track status and a strong pipeline position the company for a major 2025 launch of TNX-102SL for fibromyalgia, supported by commercial migraine products and robust R&D. Additional programs target acute stress, cocaine intoxication, and infectious diseases.